PTC Therapeutics, Inc.

PTCT Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of PTCT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
PTCT Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
PTCT Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
PTCT Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in PTCT holdings by institutional investors

Insider Trading

Quarterly net insider trading by PTCT's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $140,000 Oct 20, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
  • $120,000 Jul 21, 2025 Issue: Taxation/Internal Revenue Code Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $210,000 Apr 21, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
  • $80,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
  • $90,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
  • $90,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
  • $500,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
  • $170,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations
  • $170,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations
  • $190,000 Feb 04, 2025 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $570,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
  • $160,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $190,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $200,000 Jul 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $370,000 Apr 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $190,000 Apr 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $180,000 Oct 20, 2021 Issue: None
  • $180,000 Jul 20, 2021 Issue: None
  • $180,000 Apr 20, 2021 Issue: None
  • $180,000 Jan 21, 2021 Issue: None
  • $180,000 Oct 29, 2020 Issue: None
  • $50,000 Jul 20, 2020 Issue: Health Issues
  • $50,000 Apr 26, 2020 Issue: Health Issues
  • $50,000 Feb 25, 2020 Issue: Health Issues
  • $20,000 Apr 17, 2019 Issue: Budget/Appropriations
  • $40,000 Apr 17, 2019 Issue: Budget/Appropriations
  • $30,000 Jan 22, 2019 Issue: Budget/Appropriations
  • $60,000 Jan 22, 2019 Issue: Budget/Appropriations
  • $10,000 Jan 16, 2019 Issue: None
  • $10,000 Oct 18, 2018 Issue: Health Issues Medicare/Medicaid
  • $30,000 Oct 18, 2018 Issue: Budget/Appropriations
  • $60,000 Oct 18, 2018 Issue: Budget/Appropriations
  • $30,000 Jul 20, 2018 Issue: Budget/Appropriations
  • $60,000 Jul 20, 2018 Issue: Budget/Appropriations
  • $30,000 Apr 20, 2018 Issue: Budget/Appropriations
  • $30,000 Apr 20, 2018 Issue: Budget/Appropriations
  • $30,000 Jan 17, 2018 Issue: Budget/Appropriations
  • $30,000 Jan 17, 2018 Issue: Budget/Appropriations
  • $30,000 Oct 18, 2017 Issue: Budget/Appropriations
  • $30,000 Oct 18, 2017 Issue: Budget/Appropriations
  • $30,000 Aug 09, 2017 Issue: Budget/Appropriations
  • $30,000 Aug 09, 2017 Issue: Budget/Appropriations
  • $30,000 Jul 18, 2017 Issue: Budget/Appropriations
  • $10,000 Apr 20, 2017 Issue: Health Issues
  • $30,000 Apr 19, 2017 Issue: Budget/Appropriations
  • $10,000 Jan 19, 2017 Issue: Budget/Appropriations
  • $30,000 Jan 12, 2017 Issue: Budget/Appropriations
  • $30,000 Oct 20, 2016 Issue: Health Issues
Corporate Lobbying

PTCT Estimated quarterly lobbying spending

Revenue Breakdown

PTCT Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
PTCT Income Statement
PTCT Balance Sheet
PTCT Cash Flow
U.S. Patents

New PTCT patent grants

  • Patent Title: Compounds for treating spinal muscular atrophy Nov. 05, 2019
  • Patent Title: Substituted triazine bmi-1 inhibitors May. 22, 2018
  • Patent Title: Compounds for treating spinal muscular atrophy Mar. 13, 2018
  • Patent Title: Compounds for treating spinal muscular atrophy Jan. 30, 2018
  • Patent Title: Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy Jan. 30, 2018
  • Patent Title: Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid Jan. 23, 2018
  • Patent Title: Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use Jan. 09, 2018
  • Patent Title: Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy Aug. 22, 2017
  • Patent Title: Antibacterial compounds and methods for use May. 16, 2017
  • Patent Title: Compounds for treating spinal muscular atrophy Apr. 11, 2017
  • Patent Title: 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease Apr. 04, 2017
  • Patent Title: Compounds and methods for antiviral treatment Mar. 14, 2017
  • Patent Title: Compounds for treating spinal muscular atrophy Mar. 07, 2017
  • Patent Title: Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy Dec. 20, 2016
  • Patent Title: Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same Nov. 15, 2016
  • Patent Title: Methods and agents for screening for compounds capable of modulating gene expression Oct. 25, 2016
  • Patent Title: Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease Oct. 25, 2016
  • Patent Title: Antibacterial compounds and methods for use Aug. 09, 2016
  • Patent Title: Compounds for treating spinal muscular atrophy Jul. 26, 2016
  • Patent Title: Survival motor neuron gene (smn2) mrna constructs for post-transcription regulation Jul. 19, 2016
  • Patent Title: Methods of screening for compounds for treating muscular dystrophy using human alpha7 integrin mrna translation regulation Jun. 28, 2016
  • Patent Title: Compounds for treating spinal muscular atrophy Jun. 21, 2016
  • Patent Title: Methods for treating cancer and non-neoplastic conditions May. 31, 2016
  • Patent Title: Compounds for nonsense suppression, and methods for their use Apr. 19, 2016
  • Patent Title: Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4] oxadiazol-3-yl]-benzoic acid Apr. 12, 2016
  • Patent Title: Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith Mar. 22, 2016
  • Patent Title: Compounds for nonsense suppression, and methods for their use Mar. 01, 2016
  • Patent Title: Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control Mar. 01, 2016
  • Patent Title: Methods for dosing an orally active 1,2,4-oxadiazole Jan. 05, 2016
  • Patent Title: Compositions of 1,2,4-oxadiazol benzoic acid compounds and methods for their use Dec. 08, 2015
  • Patent Title: Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent Dec. 01, 2015
  • Patent Title: Cell based methods and systems for the identification of rna regulatory sequences and compounds that modulate their functions Jun. 30, 2015
  • Patent Title: Methods and agents for screening for compounds capable of modulating gene expression Jun. 30, 2015
  • Patent Title: Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases Jun. 09, 2015
  • Patent Title: Methods for treating spinal muscular atrophy Mar. 24, 2015
  • Patent Title: Methods for using 1,2,4-oxadiazole benzoic acid compounds Mar. 10, 2015
  • Patent Title: Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control Feb. 03, 2015
  • Patent Title: Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis Jan. 27, 2015
  • Patent Title: Screening assays for compounds that modulate programmed ribosomal frameshifting Jan. 13, 2015
  • Patent Title: Hcv inhibitor and therapeutic agent combinations Sep. 23, 2014
  • Patent Title: Methods for using 1,2,4-oxadiazole benzoic acid compounds Aug. 05, 2014
  • Patent Title: Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid Jun. 10, 2014
  • Patent Title: Methods of screening for compounds for treating muscular dystrophy using migf1 mrna translation regulation Jun. 03, 2014
  • Patent Title: Indole derivatives and methods for antiviral treatment May. 27, 2014
  • Patent Title: Methods for dosing an orally active 1,2,4-oxadiazole May. 06, 2014
  • Patent Title: Compounds for nonsense suppression and methods for their use Apr. 29, 2014
  • Patent Title: Methods for treating prostate conditions Apr. 22, 2014
  • Patent Title: Methods for treating kaposi sarcoma Apr. 15, 2014
  • Patent Title: Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and their use in bioassays Apr. 08, 2014
  • Patent Title: Bmi-1 protein expression modulators Mar. 25, 2014
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to PTCT from public contracts

PTCT News

Recent insights relating to PTCT

CNBC Recommendations

Recent picks made for PTCT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PTCT

PTCT Analyst Ratings

PTCT Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
PTCT Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $PTCT stock a Buy, Sell, or Hold?

  • What is the price target for $PTCT stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

PTCT Top Shareholders
Shareholder
Shares Held
PTCT Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $PTCT stock?

  • Who owns the most shares of $PTCT stock?

  • What funds own $PTCT stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

PTCT Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view PTCT Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About PTCT

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

  • Address Warren, NJ
  • Market Cap 6.3 billion
  • Employees 939
  • Industrial Classification Pharmaceutical Preparations
Back To Top